HCA Healthcare, Inc. HCA is reaping the benefits of a surgical boom, strategic acquisitions, and robust cash flow. The optimistic forecast for 2024 bolsters investor trust in the stock.
A Standout Zacks Rank & Strong Stock Performance
HCA Healthcare currently holds a Zacks Rank #2 (Buy).
Year to date, the stock has surged by 21.2%, outperforming the medical-hospital industry growth rate of 18.7%. The Zacks Medical sector is up by 2.2%, while the S&P 500 composite has climbed by 9.2% during the same period.
Image Source: Zacks Investment Research
Impressive Value Score
HCA Healthcare boasts an outstanding Value Score of A. A strong Value Score is indicative of undervaluation, and historically, stocks with favorable Value Scores alongside strong Zacks Ranks have proven to be sound investment choices.
Robust Growth Outlook
Estimates project HCA’s 2024 earnings to reach $20.49 per share, a 7.8% increase from the previous year. Revenue estimates sit at $69 billion, marking a 6.2% growth from last year.
The forecast for 2025 places earnings at $22.81 per share, indicating an 11.3% rise from 2024. Revenue estimates for 2025 stand at $72.5 billion, signaling a 5.1% increase from the 2024 projection.
Consistent Earnings Performance
HCA Healthcare has surpassed earnings expectations in three out of the last four quarters, with an average surprise of 9.78%.
Strong Returns on Equity
HCA’s return on equity over the past year has exceeded the industry average, highlighting the company’s efficient capital utilization.
Promising 2024 Outlook
HCA projects revenues in the range of $67.8-$70.3 billion for 2024, implying a 6.2% growth from 2023. Earnings per share are forecasted between $19.70 and $21.20, indicating a 7.6% improvement from 2023.
Driving Forces for Growth
HCA’s revenue surge is fueled by increasing patient volumes, a key revenue driver for healthcare providers. In 2023, admissions rose by 2.7%.
The company anticipates a rise in elective surgeries post the deferral period, driving occupancy levels and revenue at its surgery centers. Operating 124 freestanding surgery centers at the close of 2023 places HCA in a robust position.
The uptick in outpatient surgeries and emergency room visits is set to sustain revenue growth. In 2023, these metrics rose by 2.1% and 4.1% respectively. HCA also addresses mental health challenges through its behavioral hospitals.
Strategic acquisitions have bolstered HCA’s portfolio and national presence, with $635 million spent on such initiatives in 2023 alone.
Moreover, HCA’s virtual care offerings and technology-driven care programs enhance operational efficiency, while its strong financial position supports further growth. As of Dec 31, 2023, cash reserves surged by 3%, with operating cash flows reaching $9.4 billion in 2023.
Exploring Alternatives
Other appealing stocks in the medical domain include Medpace Holdings, Inc. MEDP, Lantheus Holdings, Inc. LNTH, and Organon & Co. OGN, boasting a Zacks Rank #1 (Strong Buy).
Medpace exceeded earnings estimates in the last four quarters, with an average surprise of 12.42%. Estimates project a significant earnings and revenue upswing for 2024.
Lantheus and Organon also present strong cases, with consistent earnings beats and optimistic outlooks for 2024.
While Medpace and Organon shares have seen substantial gains this year, Lantheus experienced a slight decline.
Exciting Offer!
For valuable insights on retirement planning, check out Zacks Investment Research’s Special Report covering 5 high-dividend stocks.
5 Dividend Stocks to Include in Your Retirement Strategy offers unconventional advice and guidance for a secure financial future.
An Insight Into the Resilient Stocks in the Healthcare Sector
A Closer Look at Leading Healthcare Stocks
Examining the Phenomenon of HCA Healthcare, Inc. (HCA)
Unveiling the Potential of Lantheus Holdings, Inc. (LNTH)
Analyzing the Healthcare Landscape
The realm of healthcare investments has always been a tumultuous sea – turbulent and unpredictable; yet, these select stocks seem to have found their anchor in turbulent waters.
As the world grapples with unforeseen challenges, the healthcare sector stands as a pillar of fortitude, with stocks like HCA Healthcare, Inc. (HCA), Lantheus Holdings, Inc. (LNTH), Medpace Holdings, Inc. (MEDP), and Organon & Co. (OGN) making waves in the market.
Investors seeking sturdy vessels in the financial tempest might find solace in these stocks, weathering storms with resilience and reliability.
The Unyielding Strength of Healthcare Stocks
Through the ebbs and flows of the market, healthcare stocks have proven to be the unsung heroes of the investment world, offering stability and growth when tumult looms large.
Amidst the chaos and uncertainty, these stocks serve as beacons of hope for investors, navigating the choppy waters with unwavering strength and resilience.
In times of adversity, HCA Healthcare, Inc. (HCA), Lantheus Holdings, Inc. (LNTH), Medpace Holdings, Inc. (MEDP), and Organon & Co. (OGN) emerge as the stalwarts of the healthcare sector, embodying unwavering dedication and steadfast performance.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
